SEC filings · customer concentration · MGNX

Macrogenics's major customers

Sanofi accounted for 33% of Macrogenics's revenue in FY 2025.

3major customers now
89%of revenue from them
0listed suppliers depending on it
2014–2026years covered
Free

Get an email when Macrogenics's customer concentration changes

When a new annual report adds a 10% customer, drops one, or moves a share by 5 points or more, you get the change and the filing link. Up to 10 companies per address, no account, unsubscribe with one click.

Major customers of Macrogenics

Customers that Macrogenics named in its annual report as 10% or more of revenue. A missing year means the customer was below that line or not named.

CustomerShare of revenueChange vs prior yearHistoryLatest filing
SanofiSNY33%newFY 2023: 10%FY 2025: 33%2 yearsFY 2025 · filed 9 Mar 2026
IncyteINCY32%▼ from 76%FY 2017: 96%FY 2018: 68%FY 2019: 35%FY 2020: 47%FY 2021: 31%FY 2022: 26%FY 2023: 53%FY 2024: 76%FY 2025: 32%9 yearsFY 2025 · filed 9 Mar 2026
GileadGILD24%newFY 2014: 11%FY 2025: 24%2 yearsFY 2025 · filed 9 Mar 2026

Formerly disclosed

CustomerShare of revenueChange vs prior yearHistoryLatest filing
Les Laboratoires Servier And Institut De Recherches Servier Servier43%last FY 2022FY 2019: 18%FY 2022: 43%2 yearsFY 2022 · filed 15 Mar 2023
Servier MGA27136%last FY 2014FY 2014: 36%1 yearFY 2014 · filed 28 Feb 2017
Janssen Biotech19%last FY 2020FY 2015: 72%FY 2016: 85%FY 2020: 19%3 yearsFY 2020 · filed 15 Mar 2023
Takeda17%last FY 2014FY 2014: 17%1 yearFY 2014 · filed 28 Feb 2017
I Mab Biopharma16%last FY 2021FY 2021: 16%1 yearFY 2021 · filed 7 Mar 2024
Imab16%last FY 2021FY 2021: 16%1 yearFY 2021 · filed 24 Feb 2022
Zai LabZLAB15%last FY 2022FY 2019: 29%FY 2020: 11%FY 2021: 30%FY 2022: 15%4 yearsFY 2022 · filed 20 Mar 2025
Boehringer Ingelheim12%last FY 2015FY 2014: 29%FY 2015: 12%2 yearsFY 2015 · filed 27 Feb 2018
Mc Kesson Plasma Biologics And Mc Kesson Specialty Care Distribution12%last FY 2023FY 2023: 12%1 yearFY 2023 · filed 9 Mar 2026
Asd Healthcare And Oncology Supply10%last FY 2023FY 2023: 10%1 yearFY 2023 · filed 9 Mar 2026
Provention Bio10%last FY 2023FY 2018: 10%FY 2022: 43%FY 2023: 10%3 yearsFY 2023 · filed 20 Mar 2025

About this data

US-listed companies must disclose revenue from any single customer that reaches 10% of their total (ASC 280). ShadowGraph reads these disclosures from the XBRL data of every 10-K and 20-F we scan, keeps one value per fiscal year (restatements replace earlier values) and links each number to its filing. Companies that describe a customer only as "Customer A" are not listed by name. Figures are as reported; nothing here is investment advice.

All companies · Latest dependency shifts · Bulk data and API